Clin Pediatr Hematol Oncol.  2022 Oct;29(2):44-51. 10.15264/cpho.2022.29.2.44.

IVIG Treatment Response and Age are Important for the Prognosis of Pediatric Immune Thrombocytopenia

  • 1Department of Medicine, College of Medicine, Yeungnam University, Daegu, Korea
  • 2Department of Clinical Pathology, School of Medicine, Kyungpook National University, Daegu, Korea
  • 3Department of Pediatrics, College of Medicine, Yeungnam University, Daegu, Korea


This study aimed to identify chronicity predictors of pediatric primary immune thrombocytopenia (ITP).
This study retrospectively reviewed the medical records of patients with primary pediatric ITP admitted to a tertiary medical center between 2010 and 2021. Forty-five patients with a platelet count <20,000/L at the time of diagnosis who were treated with intravenous immunoglobulin (IVIG) were enrolled in this study.
According to the disease phase, 28, 6, and 11 patients were classified into the newly diagnosed (ND), persistent, and chronic groups, respectively. The number of patients over 6 years of age was significantly higher in the chronic group than in the ND and persistent groups. After 14 days of IVIG treatment, more patients had a complete response in the non-chronic groups than in the chronic group. In univariate analysis of risk factor for chronic ITP, age 6 years or older and IVIG dose <2 g/kg were found to be risk factors for chronic ITP, and these two factors were also confirmed as significant risk factors in multivariate analysis.
In conclusion, in our study, patients over 6 years of age, and those who received IVIG doses less than 2 g/kg were more likely to progress to chronic ITP.


Immune thrombocytopenia; Chronic ITP; Predictive factor; Children
Full Text Links
  • CPHO
export Copy
  • Twitter
  • Facebook
Similar articles
Copyright © 2023 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: